Published in Women's Health Weekly, May 12th, 2005
"Adjuvant endocrinal therapy is presently undergoing a change. Should we continue to prescribe tamoxifen as we have been doing for the past 30 years, or should we resort to administering aromatase inhibitors for up to 5 or more years' Before initiating a large-scale change we should make every effort to find out whether there would be any long-term adverse effects on the central nervous system," wrote J.M. Wenderlein and colleagues, University of Ulm.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.